ALSO NOTED: Investors to pay $1.3 billion for Axcan; Smith & Nephew recalls knee implants;

> Canada's Axcan Pharma has agreed to a buyout by the private equity firm TPG Capital for $1.3 billion. Release

> Device maker Smith & Nephew is recalling some 600 knee implants that may contain too much iron; about 275 of the devices have already been implanted into patients. Report

> Germany's Merck KgaA won approval from the European Commission to sell a treatment kit for cyanide poisoning. Report

> Health Canada gave its blessing to Cangene's liquid formulation of a blood-disorder drug used in infants. Report

> The Chinese government announced that it intends to impose heavy punishments on makers of counterfeit drugs; in some cases, this may include the death penalty. Report

And Finally... A doctors' group wants to standardize and simplify prescription labels to make sure patients understand when and how to take their medicine. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.